Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail.

Literature DB >> 22241725

Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail.

Sauli Savolainen, Mark Konijnenberg, Manuel Bardiès, Michael Lassmann, Lidia Strigari, Carlo Chiesa, Arturo Chiti, Vappu Reijonin, Glenn Flux.

Abstract

Mesh：

Substances：

Year: 2012 PMID： 22241725 DOI： 10.1007/s00259-011-2036-1

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

6 in total

1. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

Authors: Marion de Jong; Wout A P Breeman; Roelf Valkema; Bert F Bernard; Eric P Krenning
Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057

2. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Authors: Raffaella Barone; Françoise Borson-Chazot; Roelf Valkema; Stéphan Walrand; Franck Chauvin; Lida Gogou; Larry K Kvols; Eric P Krenning; François Jamar; Stanislas Pauwels
Journal: J Nucl Med Date: 2005-01 Impact factor: 10.057

Review 3. Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

Authors: M Cremonesi; F Botta; A Di Dia; M Ferrari; L Bodei; C De Cicco; A Rossi; M Bartolomei; R Mei; S Severi; M Salvatori; G Pedroli; G Paganelli
Journal: Q J Nucl Med Mol Imaging Date: 2010-02 Impact factor: 2.346

4. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.

Authors: Cecilia Hindorf; Sarah Chittenden; Louise Causer; Val J Lewington; Helmut R Mäcke; Glenn D Flux
Journal: Cancer Biother Radiopharm Date: 2007-02 Impact factor: 3.099

5. 90Y/177Lu-DOTATATE therapy: survival of the fittest?

Authors: Boudewijn Brans; Felix M Mottaghy; Alfons Kessels
Journal: Eur J Nucl Med Mol Imaging Date: 2011-10 Impact factor: 9.236

6. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Authors: Jolanta Kunikowska; Leszek Królicki; Alicja Hubalewska-Dydejczyk; Renata Mikołajczak; Anna Sowa-Staszczak; Dariusz Pawlak
Journal: Eur J Nucl Med Mol Imaging Date: 2011-05-07 Impact factor: 9.236

6 in total

4 in total

Radiation dosimetry is a necessary ingredient for a perfectly mixed molecular radiotherapy cocktail.

1. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.

2. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.

Review 3. Dosimetry for treatment with radiolabelled somatostatin analogues. A review.

4. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors.

5. 90Y/177Lu-DOTATATE therapy: survival of the fittest?

6. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

Review 1. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

2. Defining the role for dosimetry and radiobiology in combination therapies.

Review 3. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.

Review 4. Dosimetry for radiopharmaceutical therapy.